Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

[Prophylaxis of infections post-allogeneic transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Lewalle P, Pochon C, Michallet M, Turlure P, Brissot E, Paillard C, Puyade M, Roth-Guepin G, Yakoub-Agha I, Chantepie S.

Bull Cancer. 2019 Jan 4. pii: S0007-4551(18)30305-9. doi: 10.1016/j.bulcan.2018.08.017. [Epub ahead of print] French.

PMID:
30616839
2.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.

3.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
4.

Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy.

Deluche E, Girault S, Jesus P, Monzat S, Turlure P, Leobon S, Abraham J, Daly N, Dauriac O, Bordessoule D.

Nutrition. 2017 Sep;41:120-125. doi: 10.1016/j.nut.2017.04.011. Epub 2017 May 4.

PMID:
28760421
5.

A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity.

Woillard JB, Debord J, Benz-de-Bretagne I, Saint-Marcoux F, Turlure P, Girault S, Abraham J, Choquet S, Marquet P, Barin-Le Guellec C.

Ther Drug Monit. 2017 Apr;39(2):145-156. doi: 10.1097/FTD.0000000000000381.

PMID:
28196047
6.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
7.

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, Maillard N, Tabrizi R, Marchand T, Malfuson J, Gac A, Gyan E, Mercier M, Béguin Y, Delage J, Turlure P, Marçais A, Nguyen S, Dulery R, Bay J, Huynh A, Daguindau E, Cornillon J, Régny C, Michallet M, Peffault de Latour R, Yakoub-Agha I, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):689-696. doi: 10.1038/bmt.2016.349. Epub 2017 Jan 9.

PMID:
28067872
8.

Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?

Leclerc M, Peffault de Latour R, Michallet M, Blaise D, Chevallier P, Rohrlich PS, Turlure P, Nguyen S, Jardin F, Yakoub-Agha I, Maury S; French Society of Bone Marrow Transplantation and Cell Therapy.

Blood. 2017 Mar 2;129(9):1227-1230. doi: 10.1182/blood-2016-09-726653. Epub 2016 Dec 16. No abstract available.

9.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

10.

Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.

Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC.

Cancer Med. 2016 Nov;5(11):3068-3076. doi: 10.1002/cam4.880. Epub 2016 Oct 17.

11.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).

Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerm G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H.

Bone Marrow Transplant. 2016 Jul;51(7):928-32. doi: 10.1038/bmt.2016.76. Epub 2016 Apr 4.

PMID:
27042842
12.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

13.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S.

Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23.

14.

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Am J Hematol. 2015 Sep;90(9):811-8. doi: 10.1002/ajh.24093.

15.

Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.

Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N.

Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21.

16.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C.

Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.

PMID:
25524177
17.

Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).

Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerm G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, François S, Peffault de Latour R, Yakoub-Agha I, Mohty M.

Eur J Haematol. 2015 Mar;94(3):265-9. doi: 10.1111/ejh.12430. Epub 2014 Sep 13.

18.

[Utilisation of immunosuppressants in the prevention of a graft versus host reaction: report by the SFGM-TC].

Belaiche S, Yafour N, Balcaen S, Beguin Y, Borel C, Bruno B, Godin S, Labussiere-Wallet H, Sanhamut N, Charbonnier A, de Berranger E, Konopacki-Potet J, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):197-203. doi: 10.1016/j.patbio.2014.05.010. Epub 2014 Jul 9. French.

19.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J.

Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8.

20.

[Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC].

Guillaume T, Porcheron S, Audat F, Bancillon N, Berceanu A, Charbonnier A, Dulery R, Edy N, El Cheikh J, Hermet E, Maurer N, Paul F, Konopacki-Potet J, Turlure P, Wallart A, Boulanger F, Dhédin N, Suarez F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):193-6. doi: 10.1016/j.patbio.2014.05.011. Epub 2014 Jul 1. French.

PMID:
24996843
21.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)].

Blaise D, Nguyen S, Bay JO, Chevallier P, Contentin N, Dhédin N, Duléry R, Eliaou JF, Rubio MT, Suarez F, Bulabois CE, Cornillon J, Huynh A, Magro L, Michallet M, Paillard C, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):180-4. doi: 10.1016/j.patbio.2014.05.004. Epub 2014 Jun 25. French.

PMID:
24973859
22.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)].

Nguyen S, Blaise D, Bay JO, Chevallier P, Contentin N, Dhédin N, Duléry R, Eliaou JF, Rubio MT, Suarez F, Bulabois CE, Cornillon J, Huynh A, Magro L, Michallet M, Paillard C, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):185-9. doi: 10.1016/j.patbio.2014.05.002. Epub 2014 Jun 18. French.

PMID:
24954121
23.

CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment.

Touati M, Delage-Corre M, Monteil J, Abraham J, Moreau S, Remenieras L, Gourin MP, Dmytruk N, Olivrie A, Turlure P, Girault S, Labrousse F, Preux PM, Jaccard A, Bordessoule D.

Leuk Lymphoma. 2015 Feb;56(2):332-41. doi: 10.3109/10428194.2014.917636. Epub 2014 Jun 27.

PMID:
24766492
24.

Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.

Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, Marquet P, Saint-Marcoux F.

Br J Clin Pharmacol. 2014 Oct;78(4):836-46. doi: 10.1111/bcp.12394.

25.

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.

de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d'Incan M, Dereure O, Dalle S, Dompmartin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, François S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socié G, Bagot M; French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire.

Haematologica. 2014 Mar;99(3):527-34. doi: 10.3324/haematol.2013.098145. Epub 2013 Nov 8.

26.

[Vaccination post hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report].

Rubio MT, Charbonnier A, de Berranger E, Gandemer V, Magro L, Maury S, Sterkers G, Suarez F, Dalle JH, Daguindau E, Galumbrun C, Hermet É, Reman O, Turlure P, Yakoub-Agha I; French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).

Pathol Biol (Paris). 2013 Aug;61(4):139-43. doi: 10.1016/j.patbio.2013.07.004. Epub 2013 Sep 4. French.

PMID:
24011964
27.

[Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report].

Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y, Paillard C, Suarez F, Turlure P, Alain S, Bulabois CE, Socié G, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):152-4. doi: 10.1016/j.patbio.2013.07.003. Epub 2013 Sep 4. French.

PMID:
24011961
28.

Outcome of older patients with acute myeloid leukemia in first relapse.

Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Fenaux P, Chevret S, Castaigne S, Dombret H.

Am J Hematol. 2013 Sep;88(9):758-64. doi: 10.1002/ajh.23498. Epub 2013 Aug 7.

29.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).

Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L.

Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.

PMID:
23499498
30.

Design and feasibility of a novel, rapid, and simple fluorescence 26-plex rt-PCR assay for simultaneous detection of 24 fusion transcripts in adult acute myeloid leukemia.

Laforêt MP, Turlure P, Lippert E, Cornillet-Lefebvre P, Pigneux A, Pradeau R, Feuillard J, Gachard N.

J Mol Diagn. 2013 Mar;15(2):186-95. doi: 10.1016/j.jmoldx.2012.11.004. Epub 2013 Jan 11.

PMID:
23318495
31.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H.

J Clin Oncol. 2013 Jan 20;31(3):321-7. doi: 10.1200/JCO.2011.40.3642. Epub 2012 Dec 17.

PMID:
23248249
32.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L.

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. No abstract available. Erratum in: Blood. 2014 Jun 26;123(26):4152.

33.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

34.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association.

Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Erratum in: Lancet. 2018 Feb 8;:.

PMID:
22482940
35.

mPGES-1 in leukemic cells of AML patients.

Rouaud P, Guerin E, Bordessoule D, Turlure P, Trimoreau F, Denizot Y.

Int J Hematol. 2012 Jan;95(1):115-6. doi: 10.1007/s12185-011-0999-0. Epub 2012 Jan 7. No abstract available.

PMID:
22222874
36.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.

PMID:
22177456
37.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P.

Haematologica. 2012 Feb;97(2):213-8. doi: 10.3324/haematol.2011.045914. Epub 2011 Oct 11.

38.

Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.

Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, Thomas X, Lepretre S, Huguet F, Vey N, Escoffre-Barbe M, Tavernier E, Reman O, Fegueux N, Turlure P, Rousselot P, Cahn JY, Lheritier V, Chalandon Y, Béné MC, Macintyre E, Dombret H, Ifrah N; Group for Research on Adult Acute Lymphoblastic Leukemia.

Blood. 2011 Nov 10;118(19):5099-107. doi: 10.1182/blood-2011-02-334219. Epub 2011 Aug 11.

39.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.

Leukemia. 2011 Dec;25(12):1918-21. doi: 10.1038/leu.2011.173. Epub 2011 Jul 15. No abstract available.

PMID:
21760594
40.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28.

PMID:
21715006
41.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. No abstract available.

PMID:
21468040
42.

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terré C, Fenaux P, Castaigne S, Dombret H, Boissel N; Acute Leukemia French Association (ALFA).

Haematologica. 2011 Jun;96(6):837-44. doi: 10.3324/haematol.2010.036921. Epub 2011 Apr 1.

43.

Endonasal trans-ethmoidal drainage of a cerebral abscess.

Patron V, Orsel S, Caire F, Turlure P, Bessède JP, Aubry K.

Skull Base. 2010 Sep;20(5):389-92. doi: 10.1055/s-0030-1254403.

44.

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.

Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J.

Leukemia. 2011 Jun;25(6):939-44. doi: 10.1038/leu.2011.25. Epub 2011 Feb 18.

PMID:
21331073
45.

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.

Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux P, Degos L, Chomienne C, Chevret S, Dombret H.

Oncotarget. 2010 May;1(1):34-42.

46.

Phospholipase A2 receptors in human leukemic blasts.

Amin R, Fiancette R, Bordessoule D, Turlure P, Guerin E, Trimoreau F, Denizot Y.

Leuk Lymphoma. 2011 May;52(5):908-9. doi: 10.3109/10428194.2010.551160. Epub 2011 Jan 27. No abstract available.

PMID:
21271860
47.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Haematologica. 2011 Feb;96(2):245-52. doi: 10.3324/haematol.2010.027862. Epub 2010 Oct 22.

48.

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.

Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S; French CMV Resistance Survey Study Group.

J Antimicrob Chemother. 2010 Dec;65(12):2628-40. doi: 10.1093/jac/dkq368. Epub 2010 Oct 20.

PMID:
20961907
49.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM).

Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.

50.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

Supplemental Content

Loading ...
Support Center